Long-term low dose interferon alpha-2b in the treatment of chronic hepatitis B in multi-ethnic patients in Hawaii. by Ching, Nathaniel P. H. et al.
Long Term Low Dose Interferon Alpha
2b in the Treatment of Chronic Hepatitis
B in Multi-Ethnic Patients in Hawaii
Nathaniel Ching MD ‘, James Lumeng MD **, Ronald Pang MD **, Glenn Pang MD**,
Fung Wa Or BA***, Natascha Ching BA, and Clara Ching PhD
The antiviral and immunomodulatory effects of interferon were
assessed in the treatment of chronic hepatitis B in multi-ethnic
patients to prevent viral replication and chronic liver damage. Five
million units of recombinant interferon alpha-2b were administered
three times a week for 48 weeks to a group of 18 chronic active
hepatitis B patients. A complete response was defined as
serocon version to anti-HBe and/or loss of HBe antigen.
Serocon version to anti-HBe in 5 of 12(42%) chronic active hepatitis
B patients occurredafter48 weeks of therapy. HBV..DNA decreased
to undetectable levels in 8 of 12 (67%) patients. This chronic low-
dose interferon administration regimen demonstrated responses
comparable to other studies.
Introduction
Chronic hepatitis B is a major public health problem in Hawaii
because of the large immigrant population from Asia and the Pacific
Basin. Exposure to hepatitis B virus (HBV) often results in chronic
hepatitis that can significantly increase the risk of developing
cirrhosis and hepatocellular carcinoma.’ Approximately 30,000 to
40,000 in Hawaii have been infected with hepatitis B virus (HBV).
The estimated carrier rate in Hawaii is 2-3%, higher than the 0.5%
of the mainland United States.2 In acute HBV infection in adults,
90% of those infected will develop a primary antibody response; 5
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to 10% of patients will develop chronic inflammation.3More than
90% of neonates born to HBeAg-positive mothers have been
reported to develop chronic HBV infection.45 Interferon has been
shown currently to be the most effective therapy in approximately
30 to 40% of chronic hepatitis B patients67because of its antiviral
and immunomodulatory effects. Perillo et a18 have reported hepati
tis Be antibody (anti-HBe) seroconversion and loss of HBV DNA
in patients treated with interferon with (36%) and without (37%)
prednisone. Long term remission with formation of anti-hepatitis
Bs antigen (anti-HBs) was observed by Korenman et al9 in patients
followed for 3 to 7 years after interferon alpha-2a therapy. This
represents a hopeful therapeutic option for patients who are not able
to spontaneously suppress the HBV infection immunologically.
Based on our previous experience with interferon protocols in
selected cancer patients,’° the daily administration of 5 million units
interferon daily over 16 weeks as utilized by Perillo et al8 would not
be a tolerable dose for our population in Hawaii because of the
constitutional symptoms of interferon. In our cancer patients, we
first used a lower interferon dose, 1 million units, administered three
times a week because the rest periods made this therapy more
tolerable and natural killer cell function was better maintained.’0”
The majority of our chronic hepatitis B patients were fairly
asymptomatic before therapy and gainfully employed. Fatigue and
weakness resulting from the medication would preclude many from
continuing their occupations.
A Phase II protocol was initiated to treat chronic hepatitis B
patients to determine the effect of 5 million units of recombinant
interferon alpha-2b (Schering-Plough Corporation, Kenilworth,
NJ) administered subcutaneously three times a week for a period of
48 weeks. The objective was to utilize the antiviral and
immunomodulatory effects of interferon to prevent viral replication
and the chronic liver damage with the increased risk of developing
hepatocellular carcinoma. These studies indicated that this inter
feron dose and schedule could suppress HBV replication and result
in HBeAg seroconversion and normalization of biochemical liver
function activity.
Materials and Methods
Patient Population
Adult volunteers were recruited from the database of hepatitis B
carriers maintained by the Hawaii Department of Health.’2These
patients were re-staged for HBV serological markers: hepatitis B e
antigen (HBeAg), antibody’ to HBeAg (anti-HBe), hepatitis B
surface antigen (HBsAg), antibody to HBsAg (anti-HBs) and serum
alanine aminotransferase activity (ALT), to determine the stage of
their hepatitis B infection. From this database, 17 of 95 (18%)
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patients screened had chronic active hepatitis B: HBsAg and HBeAg
positive; ALT levels were 100 IU/L± 128. Gastroenterologists also
referred patients for evaluation and therapy.
Chronic active hepatitis patients, HBeAg and HBsAg positive for
greater than 6 months, anti-HBe and anti-HBs negative, ALT levels
>1.3 x high normal (45 lUlL), were selected for therapy.
Interferon Therapy
Eighteen chronic active hepatitis B patients were treated with
recombinant interferon alpha-2b (Intron-A, Schering-Plough Cor
poration, Kenilworth, NJ). Three million units were adminstered
subcutaneously 3 times per week for 2 weeks and, if tolerated, the
dose was increased to 5 million units for a total of 48 weeks.
Patients received their injections in the Ambulatory Oncology
Clinic or chose to voluntarily self-administer their medication after
training by the Oncology Nursing Staff. The dose was reduced to 3
million units when platelets were <100,000 or granulocytes were
<1000. All patients signed written informed consent for treatment
with this interferon protocol approved by the Institutional Review
Board.
Evaluation During Therapy
Patients were evaluated during therapy for hematological, bio
chemical and serological profiles. Blood was collected for complete
blood and platelet counts; liver function tests including serum
alanine and aspartate aminotransferase and gamma glutamyl
transpeptidase activities (ALT, AST, GGPT) prior to therapy, after
2 weeks, monthly during therapy and 2-3 months post therapy. The
serological markers for HBV, HBeAg/anti-HBe and HB5Ag/anti-
HBs, were evaluated at baseline, after 6 months, at the completion
of therapy, and 2-3 months post therapy by the Enzyme Immunoas
say (Abbott Laboratories, Abbott Park, Ii). All evaluations were
performed by the same Clinical and Reference Laboratories.
A complete response was defined by loss of HBeAg and/or the
formation of anti-HBe or anti-HBs; non-responders showed persis
tence of HBeAg. A clinical response was defined as the normaliza
tion of serum ALT levels.
HBV DNA Assay
A sensitive and quantitative radiological molecular solution hy
bridization assay kit for RBV-DNA generously supplied by Abbott
Laboratories (Abbott Park, IL) was used for evaluating viral repli
cation and monitoring antiviral therapy.’3Aliquots of serial serum
samples from each patient stored at -70C were tested for HBV DNA
at baseline, 2-3 months intervals, the end of therapy and 2-3 months
following therapy. The assay utilizes a single-stranded I-labeled
DNA probe complementary to HBV DNA sequences and with a
minimum specific activity of 10 cpmlj.tg. Sensitivity of the assay
was 1.5 pg HBV DNA per ml of serum or approximately 4.5 x 10E5
HBV genomes per ml serum.
Statistical Analysis
Results are expressed as arithmetic mean ± S.D. except where
noted. Data was analyzed with the Sigma Stat program (Jandel
Scientific, San Rafael, CA). Continuous variables were analyzed by
linear regression and/or the non-parametric Kruskal-Wallis tech
nique. The IBM 55SX and PS8O PC computers were used.
Results
Study Population
The average age of the chronic active patients was 33 ± 10 yrs; 10
of the 18(56%) were males. Baseline liver function tests (ALT, AST
and GGPT) were increased in the chronic active patients: ALT = 96
± 74 lU/L, AST = 62 ± 39 lU/L, GGPT = 141 ± 304 IU. Immigrants
from Vietnam represent the major ethnic group of patients (39%);
Filipinos, 22%; Chinese, 17%. All were gainfully employed,
housewives or students except for three unemployed medicaid
recipients.
Toxicity
With this interferon protocol at a reduced dose of 5 million units
three times a week, 6 of 18 (33%) patients ceased therapy on their
own choice. Their reasons included: inability to care for family(2)
or to tolerate the side effects.(2) Two gave no reason for terminating
treatment.
Although we used a lower dose IFN protocol, 3 of 18 (17%)
chronic active patients required dose reduction from 5 to 3 million
units because of intolerable constitutional symptoms. In two pa
tients, platelets decreased below lOOK. One patient on Dilantin
required a dose reduction to 1.5-2 million units because of
granulocytopenia.
Biochemical Liver Function Tests
Assessment of biochemical studies for liver function revealed
increased ALT levels in the chronic active hepatitis patients which
returned to normal levels in those completing 48 weeks of therapy,
p < .05 by ANOVA analysis (Figure 1). This occurred whether or
not seroconversion occurred. The non-responders had flares ofALT
levels after discontinuation of interferon therapy.
Serology of HBV Markers
Serological markers for HBsAg/anti-HBs and HBeAg/anti-RBe
were assessed to determine the outcomes. Loss of HBeAg and
seroconversion to anti-HBe occurred inS of 12(42%) patients after
interferon therapy with no relation to the dose received. One patient
responded after only six months of therapy; a sixth patient was RBV
DNA and RBeAg negative after six months of therapy but did not
form anti-HBe. In chronic active patients requiring the full 48 weeks
of therapy, antibodies to HBeAg were not detected until 2-3 months
post therapy. Seroconversion of RBsAg was not observed. Of the
six responders, five were U.S. citizens and there was one female
immigrant. Sex was equally distributed.
Fig 1 —Changes in ALT levels of chronic active hepatitis B patients on interferon
therapy, X ± SD. Elevated levels at baseline decreased to normal levels in those
patients completing the 48 weeks of therapy (P<.05).
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The remaining six patients were non-responders (HBeAg+,
BHeAb-). Follow-up studies will be continued. The ethnicity of the
six non-responders of the chronic active hepatitis B patients were
Vietnamese (2) and Chinese (2) immigrants, and Filipino (2) born
in Hawaii. The six who ceased therapy were not evaluable and were
also immigrants, Vietnamese (5) and Chinese (1).
HBV-DNA
Ten of the twelve patients had elevated levels of HBV-DNA
before therapy. All six responders had no detectable HBV-DNA
after treatment. Two of the six non-responders did not have measur
able levels of HBV-DNA after therapy although no HBV antibodies
were formed.
Discussion
In this study with multi-ethnic patients, we observed the antiviral
effect of interferon in 67% chronic active hepatitis B patients who
showed progressive decline in HBV DNA during therapy. We
achieved a 42% HBeAg seroconversion and HBeAb formation rate
in patients who completed the 48-week interferon course. This
Phase II protocol of 5 million units interferon alfa-2b administered
subcutaneously three times a week for 48 weeks to patients with
hepatitis B infection yielded comparable results as reported by
Perillo et a18 using 5 million units daily for 16 weeks and including
pretreatment with prednisone. HBeAg seroconversion occurred in
30 to 40% of their patients with loss of HBV DNA in 40 to 50%.
Similar rates of seroconversion were reported by Reichen et al’4
with either 1.5 or 5 million units interferon alpha 2b three times a
week for 4 months with and without a preliminary course of
prednisone therapy. HB sAg seroconversion was not observed in our
studies although Korenman et al have reported that anti-HBs may
appear at an average of 3 years after treatment.
We have used an interferon dose and schedule of 5 million units
three times a week subcutaneously over a longer period of 48 weeks
with minimal effect on blood counts. This Phase II protocol would
allow greater tolerance of this medication in chronic hepatitis B
patients. After approximately 9 months, the cumulative dose of
interferon would be equivalent to the daily administration of 5
million units for 16 weeks as used by Perillo et al.8 Furthermore,
patients treated in an outpatient environment would be able to
continue their productive work to minimize economic loss.
With this interferon dose, however, six (33%) Asian immigrant
patients still discontinued treatment. The constitutional symptoms
were most disturbing to these patients who were essentially
asymptomatic before therapy. Some were unable to continue work
ing. Our cancer patients have tolerated higher doses but may be
more motivated to continue than the chronic hepatitis B patients.
Hawaii has a large percentage of affected Asian-Pacific patients
because of the large immigrant population.2’The Asian male has
been observed to be the most resistant to treatment.’5Lok et al’6
reported spontaneous seroconversion in 31 of 142 (22%) HBeAg
positive Chinese patients observed up to 60 months. They predicted
a 17% one year seroconversion rate. However, none of our Asian
non-responders demonstrated seroconversion one year after comple
tion of interferon therapy.
In this study, most of our non-responders were Asian male
immigrants; male responders were USA or Hawaii-born. Three
female responders, two Hawaii-born and a Filipino immigrant had
progressive decline in HBV DNA after interferon therapy. A
sustained therapeutic effect in these young females may prevent the
vertical transmission of HBV to their newborn and subsequent
chronic antigenemia.
We monitored the antiviral effect of interferon by serial quantitation
for HBV-DNA using the solution hybridization assay. Eight of
twelve (67%) chronic active hepatitis patients had undetectable
levels of HBV DNA after the end of therapy. An antiviral effect of
interferon is indicated with no seroconversion, as yet, in 2 non-
responders. Follow-up studies are planned in these non-responders
with no detectable HBV DNA.
Our diverse group of Asian patients represents a major public
health problem and challenge for developing effective therapeutic
interventions in Hawaii. The possibility exists that these patients
may have had prolonged infection since childhood resulting in the
transcription of virus to their hepatocytes and may be more resistant
to interferon therapy. The elimination of chronic HBV infection is
greatest if treated relatively early when viral HBV DNA exists in the
non-integrated or episomal state.’7With the high carrier rate in
Hawaii, early detection and treatment as well as vaccination will be
necessary for the prevention of the sequelae of chronic HBV
infection.
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